Paper published in a journal (Scientific congresses and symposiums)
HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon
Nelson, D; Andreone, P; Colombo, M et al.
2014In Hepatology, 60 (S1)
Peer Reviewed verified by ORBi
 

Files


Full Text
AASLD faldaprevir.pdf
Publisher postprint (913.36 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] In treatment-naïve, non-cirrhotic patients with HCV GT1b infection, faldaprevir + deleobuvir + ribavirin for 16 or 24 w resulted in comparable SVR 12 rates (76% vs 82%) with similar tolerability profiles. Patients with cirrhosis achieved SVR 12 of 74% (24w). The adjusted SVR rates for 16 or 24w in patients with or without cirrhosis were significantly higher than historical control.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Nelson, D
Andreone, P
Colombo, M
Calinas, F
Olveira, A
DELWAIDE, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Haussinger, D
Ouzan, D
Strasser, S
Asselah, T
Cooper, C
Stern, J
Boecher, W
Kukolj, G
Aslanyan, S
Deng, Q
Wang, E
Mensa, F
More authors (8 more) Less
Language :
English
Title :
HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon
Publication date :
October 2014
Event name :
The Liver Meeting 2014
Event date :
du 7 novembre 2014 au 11 novembre 2014
Audience :
International
Journal title :
Hepatology
ISSN :
0270-9139
eISSN :
1527-3350
Publisher :
Wiley, Hoboken, United States - New Jersey
Volume :
60
Issue :
S1
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 December 2014

Statistics


Number of views
57 (0 by ULiège)
Number of downloads
116 (0 by ULiège)

Bibliography


Similar publications



Contact ORBi